Foundation Medicine Expands Collaboration with Bristol Myers Squibb for Sequencing Companion Diagnostic
Foundation Medicine has announced an expansion of its collaboration with Bristol Myers Squibb to develop FoundationOne®CDx as a next-generation sequencing companion diagnostic. This diagnostic aims to identify patients with homozygous MTAP deletion for various indications related to an investigational targeted therapy, further advancing their efforts in biomarker-driven therapies.
BOSTON–(BUSINESS WIRE)–Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne®CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. The expansion broadens Foundation Medicine’s longstanding relationship in advancing biomarker-driven therapies with Br